- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT01688323
Finding Predictors of Side Effects to Chemoradiation Treatment in Elderly Patients With Head and Neck Cancer
Identification of Predictors of Tolerance to Chemoradiotherapy in Elderly Patients With Head and Neck Cancer
연구 개요
상세 설명
Purpose: To identify baseline predictors of change in function over the course of treatment with chemoradiotherapy in patients with head and neck cancer.
Participants: Patients 65 or older who have an appointment at the North Carolina Cancer Hospital (NCCH) or other participating sites, have planned chemoradiotherapy for head and neck cancer
Procedures (methods): Consenting subjects will complete a Geriatric Assessment, Functional Assessment of Cancer Therapy - Head and Neck and give a blood sample for CBC and p16INK4a at the start of their chemoradiotherapy, at week four, at the end and 90 days post therapy. They will also complete a health behavior questionnaire at baseline.
연구 유형
등록 (실제)
연락처 및 위치
연구 장소
-
-
North Carolina
-
Chapel Hill, North Carolina, 미국, 27514
- UNC Lineberger Comprehensive Cancer Center
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
샘플링 방법
연구 인구
설명
Inclusion Criteria
- Patients will be eligible for this protocol provided they have an appointment at the North Carolina Cancer Hospital (NCCH), have planned chemoradiotherapy for head and neck cancer (any histology) and consent to complete the Geriatric Assessment. No exclusions will be made based on gender, ethnicity, performance status or race. Patient must be able to read and speak English.
- Signed, IRB approved written informed consent.
- Age of at least 65 years.
- Enrollment in other studies, both therapeutic and observational, will not result in exclusion.
Exclusion Criteria
- Inability to read and speak English.
- Inability to comply with study for any other reason than language
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
코호트 및 개입
그룹/코호트 |
개입 / 치료 |
|---|---|
|
Elderly Chemorads
Elderly patients with Head and Neck Cancer who are Undergoing Chemotherapy
|
Each subject will be administered the appropriate surveys and blood draws over the course of the study.
다른 이름들:
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Significant Change in Function from Baseline to Post-Treatment
기간: 2 years
|
To determine if there is a significant change in the Instrumental Activities of Daily Living (IADL) subscore of the Geriatric Assessment (GA) from baseline to 90 days post-treatment.
|
2 years
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Explore Association between Baseline Measures and Decline in Living Status
기간: 2 years
|
To explore the association of baseline measures with time to decline in living status.
(For example, completely independent to requiring home help, or requiring home help to moving to a nursing home, etc.)
|
2 years
|
|
Explore Association of Baseline Measures with Grade 3 or Higher Toxicity
기간: 2 years
|
To explore the association of baseline measures with the occurrence of any grade 3 or higher toxicity as a consequence of chemoradiotherapy.
|
2 years
|
|
Explore Association of Baseline p16 with Baseline GA Measures
기간: 2 years
|
To explore the association of baseline p16 expression with baseline subscores of the Geriatric Assessment.
|
2 years
|
|
Explore Changes in p16 Expression, GA Subscales and FACT-HN Scores Over Time.
기간: 2 years
|
To explore changes in p16 expression, GA subscales, and FACT-HN scores over the course of treatment
|
2 years
|
|
Explore Association between Baseline Measures and Changes in IADL Subscore
기간: 2 years
|
To explore the association of baseline measures with change in IADL subscore.
|
2 years
|
공동 작업자 및 조사자
수사관
- 수석 연구원: Jared Weiss, MD, University of North Carolina
간행물 및 유용한 링크
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (실제)
연구 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (추정)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .